Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 4/20 | 0.55 |
| ▸ | CALCR | P30988 | 4/20 | 0.53 |
| ▸ | KDM1A | O60341 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | KDM5A | P29375 | 1/20 | 0.53 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | GLP1R | P43220 | 1/20 | 0.52 |
| ▸ | SCTR | P47872 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30358141 | 0.91 | APLNR (0.63) | APLNRF2CALCRKDM1AMAOB | |
| SCHEMBL31182755 | 0.90 | CALCR (0.60) | APLNRF2CALCREP300HIF1A | |
| SCHEMBL30712933 | 0.90 | C5AR1 (0.62) | APLNRCALCRKDM1AMAOBKDM5A | |
| SCHEMBL30495787 | 0.90 | C5AR1 (0.66) | GLP1RKEAP1 | |
| SCHEMBL29849478 | 0.88 | MC4R (0.60) | CALCRMC4RCRHR1CRHR2GLP1R | |
| SCHEMBL30262194 | 0.87 | APLNR (0.57) | APLNRF2CALCRKDM1AKEAP1 | |
| SCHEMBL30252487 | 0.87 | CALCR (0.60) | APLNRCALCRMC4RCRHR1CRHR2 | |
| SCHEMBL30432183 | 0.87 | F2 (0.59) | APLNRF2CALCRKDM1A | |
| SCHEMBL30974429 | 0.87 | MC4R (0.61) | F2CALCRKDM1AMC4RKEAP1 | |
| SCHEMBL29707431 | 0.87 | MC4R (0.62) | CALCRKDM1AMAOBKDM5AKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352395-B2 | Anticancer peptides | IDP DISCOVERY PHARMA, S.L. (ES) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352395-B2 | Anticancer peptides | PNISR, NGLY1, SLC1A5 | APLNR 199/4885F2 4327/4885CALCR 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.